Trefoil completes series A funding supporting corneal disease treatment

Trefoil Therapeutics has raised $28 million in Series A financing, which will be used to support its phase 2a proof-of-concept study in corneal endothelial dystrophy, the company announced in a press release.

The financing was led by Bios Partners, with Access Biotechnology, Hatteras Venture Partners, Aju IB Investment, Correlation Ventures, ExSight Ventures and InFocus Capital Partners participating as well.

TTHX1114, the company’s lead product candidate, is a form of the FGF-1 protein designed to reverse vision loss by stimulating endothelial cell proliferation and migration, the release said. Preclinical data have shown it can quicken corneal clearing in animal models of corneal endothelial dystrophy and enhance healing in corneal chemical injury and herpetic keratopathy.

“Trefoil is developing TTHX1114 with the goal of providing the first regenerative therapeutic agent for the treatment of corneal dystrophy to reverse the vision loss associated with these conditions without the need for surgery for many patients,” David Eveleth, PhD, Trefoil co-founder and CEO, said in the release.

The company expects to file an investigational new drug application for TTHX1114 in corneal endothelial dystrophy in 2020 and then initiate a clinical study.

The funding will also allow Trefoil to begin studies to support an IND application for the treatment of ulcerative conditions of the cornea.

Trefoil Therapeutics has raised $28 million in Series A financing, which will be used to support its phase 2a proof-of-concept study in corneal endothelial dystrophy, the company announced in a press release.

The financing was led by Bios Partners, with Access Biotechnology, Hatteras Venture Partners, Aju IB Investment, Correlation Ventures, ExSight Ventures and InFocus Capital Partners participating as well.

TTHX1114, the company’s lead product candidate, is a form of the FGF-1 protein designed to reverse vision loss by stimulating endothelial cell proliferation and migration, the release said. Preclinical data have shown it can quicken corneal clearing in animal models of corneal endothelial dystrophy and enhance healing in corneal chemical injury and herpetic keratopathy.

“Trefoil is developing TTHX1114 with the goal of providing the first regenerative therapeutic agent for the treatment of corneal dystrophy to reverse the vision loss associated with these conditions without the need for surgery for many patients,” David Eveleth, PhD, Trefoil co-founder and CEO, said in the release.

The company expects to file an investigational new drug application for TTHX1114 in corneal endothelial dystrophy in 2020 and then initiate a clinical study.

The funding will also allow Trefoil to begin studies to support an IND application for the treatment of ulcerative conditions of the cornea.